Therapeutic method and medicament for HTLV-1 associated myelopathy
AssigneesSt. Marianna University School of Medicine, Kyowa Hakko Kirin Co., Ltd.
InventorYoshihisa Yamano
Life of this patent
Estimating the term…
Abstract
The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 (also known as human T lymphotropic virus type-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.
Claims18
A therapeutic method, comprising reducing expression level of a cytokine produced by a human T cell leukemia virus type-1 (HTLV-1)-infected cell in a HTLV-1 associated myelopathy (HAM) patient or an asymptomatic HTLV-1 carrier (AC), by administering an anti-human CC-chemokine receptor 4 (CCR4) antibody to the HAM patient or the AC.
A method for reducing an expression level of a cytokine produced by a human T cell leukemia virus type-1 (HTLV-1)-infected cell in a HTLV-1 associated myelopathy (HAM) patient or an asymptomatic HTLV-1 carrier (AC), by administering an anti-human CC-chemokine receptor 4 (CCR4) antibody to the HAM patient or the AC.
Dependencies are inferred from the claim text.